<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Merck (MRK) And Daiichi Sankyo&#x27;s R-DXd Receives FDA Breakthrough Therapy Designation — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Merck (MRK) And Daiichi Sankyo&#x27;s R-DXd Receives FDA Breakthrough Therapy Designation</h2>
    <div class="badge">2025-09-15T17:27:14+00:00</div>
    <ul>
      <li>Current share prices reflect a discount of approximately 23.6% compared to the consensus analyst price target of US$102.33.</li>
<li>Over the past five years, Merck&#x27;s total shareholder return, incorporating both share price appreciation and dividends, was 21.17%.</li>
<li>Notably, its yearly performance has also been weaker compared to peers in the US Pharmaceuticals industry, which saw a 12.5% decline.</li>
<li>This figure illustrates a steady growth trajectory, yet the company has underperformed the US market&#x27;s 18.5% return over the past year.</li>
<li>Merck experienced a 6% rise in its share price over the last quarter, coinciding with significant developments such as the FDA granting Breakthrough Therapy Designation for raludotatug deruxtecan—a potential first-in-cla</li>
<li>Find out which 28 stocks are leading the charge.</li>
<li>We&#x27;ve discovered 1 weakness for Merck that you should be aware of before investing here.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Merck%20%28MRK%29%20And%20Daiichi%20Sankyo%27s%20R-DXd%20Receives%20FDA%20Breakthrough%20Therapy%20Designation%0A%E2%80%A2%20Current%20share%20prices%20reflect%20a%20discount%20of%20approximately%2023.6%25%20compared%20to%20the%20consensus%20analyst%20price%20target%20of%20US%24102.33.%0A%E2%80%A2%20Over%20the%20past%20five%20years%2C%20Merck%27s%20total%20shareholder%20return%2C%20incorporating%20both%20share%20price%20appreciation%20and%20dividends%2C%20was%2021.17%25.%0A%E2%80%A2%20Notably%2C%20its%20yearly%20performance%20has%20also%20been%20weaker%20compared%20to%20peers%20in%20the%20US%20Pharmaceuticals%20industry%2C%20which%20saw%20a%2012.5%25%20decline.%0A%E2%80%A2%20This%20figure%20illustrates%20a%20steady%20growth%20trajectory%2C%20yet%20the%20company%20has%20underperformed%20the%20US%20market%27s%2018.5%25%20return%20over%20the%20past%20year.%0A%E2%80%A2%20Merck%20experienced%20a%206%25%20rise%20in%20its%20share%20price%20over%20the%20last%20quarter%2C%20coinciding%20with%20significant%20developments%20such%20as%20the%20FDA%20granting%20Breakthrough%20Therapy%20Designation%20for%20raludotatug%20deruxtecan%E2%80%94a%20potential%20first-in-cla%0A%E2%80%A2%20Find%20out%20which%2028%20stocks%20are%20leading%20the%20charge.%0A%E2%80%A2%20We%27ve%20discovered%201%20weakness%20for%20Merck%20that%20you%20should%20be%20aware%20of%20before%20investing%20here.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fmerck-mrk-and-daiichi-sankyo-s-r-dxd-receives-fda-breakthrough-therapy-designati%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/merck-mrk-daiichi-sankyos-r-172714735.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>